Direct-acting antivirals for chronic Hepatitis C are effective and safe
an observational study in Londrina/PR
DOI:
https://doi.org/10.1590/s2175-97902022e19925Keywords:
Hepatitis C, Drug therapy, Effectiveness, SafetyAbstract
This study aimed to evaluate the effectiveness and safety of direct-acting antivirals in a Unified Health System pharmacy of Londrina, Brazil. A descriptive observational study was performed from June 2017 to June 2018. Sociodemographic, clinical, and therapeutic variables of patients were collected from secondary data sources. Effectiveness was evaluated by sustained virologic response (SVR) and safety was evaluated by adverse events (AEs) and drug interactions (DIs). The mean population (N=30) was 56.6±11.3 years old and almost all patients had comorbidities (93.3%) and concomitant drugs (96.7%). Effectiveness evaluation was possible in 17 patients, and all of them (100.0%) achieved SVR. Eighteen patients (60.0%) reported 38 AEs, mostly mild, such as stomach symptoms and headache. No statistical relation was found between AE occurrence and treatment duration, Ribavirin use, number of comorbidities or number of concomitant drugs. A total of 48 DIs were reported, 18 being severe, and were managed by the pharmacist. The study indicates that the treatment was effective and safe.
Downloads
References
Alam I, Brown K, Donovan C, Forlenza J, Lauwers K, Mah’moud MA, et al. Real-world effectiveness of simeprevir-containing regimens among patients with chronic hepatitis C virus: The SONET Study. Open Forum Infect Dis. 2016;4(1):1-8.
Brasil. Ministério da Saúde, Secretaria de Atenção à Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Portaria n.º 84, de 19 de dezembro de 2018. Torna pública a decisão de atualizar o Protocolo Clínico e Diretrizes Terapêuticas para hepatite C e coinfecções, no âmbito do Sistema Único de Saúde - SUS. Diário Oficial da União. 20 dez 2018; Seção I.
Brasil. Ministério da Saúde, Secretaria de Vigilância em Saúde. Boletim Epidemiológico 17: Hepatites Virais. Brasília: Ministério da Saúde; 2019. [citado 2019 10 6]. Disponível em: Disponível em: http://aids.gov.br/pt-br/pub/2019/boletim-epidemiologico-de-hepatites-virais-2019
» http://aids.gov.br/pt-br/pub/2019/boletim-epidemiologico-de-hepatites-virais-2019
Brasil. Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de DST, AIDS e Hepatites Virais. Protocolo clínico e diretrizes terapêuticas para hepatite C e coinfecções. Brasília: Editora MS; 2015.
Bruno G, Saracino A, Fabrizio C, Scudeller L, Milano E, Dell’acqua R, et al. Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir±ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study. Int J Antimicrob Agents. 2017;49(3):296-301.
Chen-Hua L, Chun-Jen L, Tung-Hung S, Hung-Chih Y, Chun-Ming H, Tai-Chung T, et al. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. J Gastroenterol Hepatol. 2018;33(3):710-717.
Ferreira V, Pontarolo R. Contextualização e avanços no tratamento da Hepatite C: uma revisão da literatura. Visão Acadêmica. 2017;18(1):78-96.
Goldman L, Schafer AI. Cecil: Medicina. 24th ed. Rio de Janeiro: Elsevier; 2014.
Leventer-Roberts M, Hammerman A, Brufman I, Hoshen M, Braun M, Ashur Y, et al. Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: a population-based observational study. PLoS One. 2017;12(7):1-14.
Margusino-Framiñán L, Cid-Silva P, Mena-De-Cea A, Rodríguez-Osorio I, Pernas-Souto B, Delgado-Blanco M, et al. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C vírus infected patients: results in real clinical practice. Rev Esp Quimioter. 2019;32(2):137-144.
Naranjo CA, Busto U, Sellers E M, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-252.
Pin-Nan C, Yen-Cheng C, Shih-Chieh C, Hung-Chih C. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. J Formos Med Assoc. 2018;118(5):907-913.
Ridruejo E, Cheinquer H, Marciano S, Mendizabal M, Piñero F, Wolff FH, et al. BARCOS (Brazilian Argentine Hepatitis C Collaborative Observational Study): effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin. J Viral Hepat. 2019;26(10):1200-1209.
Souza EV Jr, Silva SR, Nunes GA, Santos LV, Souza DF, Lopes NS, et al. Public expenses with hospitalizations due to viral hepatitis. J Nurs UFPE on line. 2019;13:e240109.
University of Liverpool. Hep-Drug Interactions, [Internet]. 2019. Available: http://hep-druginteractions.org
» http://hep-druginteractions.org
World Health Organization. WHO. Uppsala Monitoring Centre. Guidelines for Setting up and Running a Pharmacovigilance Centre. Uppsala: WHO Collaborating Centre; 2000.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
